NMC
NEA Management Company Portfolio holdings
AUM
$1.33B
This Quarter Return
+22.64%
1 Year Return
+85.82%
3 Year Return
+531.37%
5 Year Return
+304.32%
10 Year Return
+4,927.96%
AUM
$1.33B
AUM Growth
+$1.33B
(+2.3%)
Cap. Flow
-$168M
Cap. Flow
% of AUM
-12.65%
Top 10 Holdings %
Top 10 Hldgs %
81.33%
Holding
39
New
1
Increased
4
Reduced
2
Closed
6
Top Buys
| 1 |
Oric Pharmaceuticals
ORIC
|
$19.5M |
| 2 |
Celcuity
CELC
|
$13.9M |
| 3 |
Trevi Therapeutics
TRVI
|
$10.1M |
| 4 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$6.66M |
| 5 |
ZBIO
Zenas BioPharma, Inc. Common Stock
ZBIO
|
$1.16M |
Top Sells
| 1 |
TEM
Tempus AI, Inc. Class A Common Stock
TEM
|
$126M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$40.2M |
| 3 |
X4 Pharmaceuticals
XFOR
|
$27.5M |
| 4 |
RGLS
Regulus Therapeutics
RGLS
|
$11.3M |
| 5 |
DM
Desktop Metal, Inc.
DM
|
$7.07M |
Sector Composition
| 1 | Healthcare | 91.51% |
| 2 | Consumer Staples | 8.49% |
| 3 | Industrials | 0.01% |
| 4 | Communication Services | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $247M | 18.56% | 3,745,262 | – | – |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $214M | 16.11% | 2,263,138 -425,427 | -16% | -$40.2M |
|
3
Rhythm Pharmaceuticals
RYTM
$6.85B
| $184M | 13.84% | 2,909,956 | – | – |
|
4
Coursera
COUR
$1.88B
| $113M | 8.49% | 12,867,769 | – | – |
|
5
CRISPR Therapeutics
CRSP
$4.71B
| $77.2M | 5.81% | 1,587,854 | – | – |
|
|
6
Trevi Therapeutics
TRVI
$883M
| $72.3M | 5.44% | 13,222,228 +1,851,852 | +16% | +$10.1M |
|
7
Savara
SVRA
$567M
| $55.8M | 4.2% | 24,471,264 | – | – |
|
|
8
Oric Pharmaceuticals
ORIC
$994M
| $41.8M | 3.15% | 4,118,621 +1,923,076 | +88% | +$19.5M |
|
|
MBX
9
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $41.2M | 3.1% | 3,614,486 | – | – |
|
10
Monte Rosa Therapeutics
GLUE
$296M
| $34.7M | 2.61% | 7,692,298 | – | – |
|
11
Aurinia Pharmaceuticals
AUPH
$1.58B
| $33.6M | 2.53% | 3,969,834 | – | – |
|
|
12
Celcuity
CELC
$2.17B
| $30.6M | 2.31% | 2,294,261 +1,044,260 | +84% | +$13.9M |
|
|
ZBIO
13
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $26.5M | 1.99% | 2,733,719 +119,771 | +5% | +$1.16M |
|
14
Gossamer Bio
GOSS
$562M
| $22.3M | 1.68% | 18,093,034 | – | – |
|
15
NeueHealth
NEUE
$59.2M
| $18.8M | 1.42% | 2,726,917 | – | – |
|
16
Phathom Pharmaceuticals
PHAT
$864M
| $18.8M | 1.42% | 1,960,169 | – | – |
|
17
Korro Bio
KRRO
$217M
| $13.6M | 1.03% | 1,090,793 | – | – |
|
18
Champions Oncology
CSBR
$93.8M
| $12.6M | 0.95% | 1,713,720 | – | – |
|
19
CVRx
CVRX
$205M
| $11.9M | 0.9% | 2,026,083 | – | – |
|
20
Black Diamond Therapeutics
BDTX
$157M
| $11M | 0.83% | 4,448,757 | – | – |
|
|
INZY
21
DELISTED
Inozyme Pharma
INZY
| $9.75M | 0.73% | 2,437,689 | – | – |
|
22
Senti Biosciences
SNTI
$38.5M
| $7.97M | 0.6% | 3,775,615 | – | – |
|
|
OMDA
23
Omada Health, Inc. Common Stock
OMDA
$1.36B
| $6.66M | 0.5% | +364,115 | New | +$6.66M |
|
24
Nkarta
NKTX
$151M
| $5.92M | 0.45% | 3,568,781 | – | – |
|
|
IVA
25
Inventiva
IVA
$861M
| $4.67M | 0.35% | 1,462,586 | – | – |
|